Navigation Links
Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
Date:10/29/2010

ligible subjects received escitalopram plus either placebo or Vyvanse (dose optimized over the range of 20 to 50 mg per day) on a 1:1 basis.

The primary study endpoint was the mean change in the total MADRS score after 6 weeks of blinded treatment in the non-remitter subset (n=129) of the randomized population, defined as subjects with a total MADRS score of >10 after the 8 week escitalopram treatment. The significance level was prospectively set at 10%.

Vyvanse demonstrated improvement compared to placebo on the mean total MADRS of -2.3 [90% CI -4.5 to -0.1] after 6 weeks of treatment in the primary analysis of non-remitting subjects (p=0.090). An additional pre-planned analysis was conducted among subjects who had a total MADRS score >10 and achieved < 50% improvement in total MADRS score (n=86). This analysis found an endpoint LS mean difference between Vyvanse and placebo of -3.9 [90% CI -6.5 to -1.3; p=0.0132 (not adjusted for multiplicity)]. The most commonly reported adverse events (dry mouth, headache, decreased appetite, and insomnia) in the trial were consistent with the known, labeled profile of VYVANSE in ADHD. Mean blood pressure and mean heart rate changes were also consistent with the product label. No notable mean ECG changes or mean changes in clinical laboratory assessments were reported in this study. The mean dose per day of VYVANSE used for adjunctive therapy with escitalopram was 29.6 mg.

"Only about 30 to 33 percent of patients will achieve full symptom remission with the first step standard antidepressant treatment," said Madhukar H. Trivedi, Professor of Psychiatry at University of Texas Southwestern Medical School. "Therefore, almost two-thirds of patients starting an antidepressant will need a second or third step treatment to achieve symptom relief. We are encouraged by the signal findings we've seen in this Phase 2 study and look forward to further evaluating Vyvanse for adjunctive treatment of patients w
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
2. Change of Name to Shire plc
3. Shires New Product Portfolio Delivers Strong Quarterly Performance
4. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
5. Shire plc: Change to Directors Details
6. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
7. Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
8. Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
9. Shire Announces Opening of Office in Japan
10. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
11. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... SonaCare Medical, a leading manufacturer of ... participated in the American Urology Association’s (AUA) surgical ... opinion leaders in urology presented on the latest ... masses while attendees had the opportunity to evaluate ... labs. Attendees at the Los Angeles, CA lab, ...
(Date:11/26/2014)... 25, 2014 The Pittcon marketing department ... conference and exposition mobile app, Pittcon ... in the App Store for iOS and Android devices ... tool before, during and after the event. It acts ... exhibiting companies, technical sessions, Conferee Networking sessions and short ...
(Date:11/26/2014)... Boston, MA (PRWEB) November 26, 2014 ... and collaboration company is proud to announce that Darren ... Development and Sales. Darren will drive the ... and positive customer experience. , Darren brings ... He has held key roles in channel operations, from ...
(Date:11/26/2014)... 2014 Theravalues Corporation est fier d,annoncer ... européen au salon Hi Europe 2014 (du 2 ... Curcumine la plus biodisponible actuellement sur ... à des ingrédients approuvés par les règlements européens. ... présent dans la racine de curcuma ( Curcuma ...
Breaking Biology Technology:SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Pittcon Releases 2015 Mobile App 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3
... , , WARSAW, ... ZMH ; SWX: ZMH) today announced the launch of the new ... surgeons and subject matter experts to develop a unique model for ... Surgeon-to-Surgeon programs under one, consolidated service offering, the enhanced Zimmer Institute ...
... EL SEGUNDO, Calif., July 27 NASA has exercised a ... continuing support to the Space Life Sciences Directorate at NASA,s Johnson ... The work will be done by Wyle,s Integrated Science and ... the bioastronautics contract, Wyle,s work supports the International Space Station, space ...
... , SOUTH PLAINFIELD, N.J., July 27 ... Phase 2 clinical trial of PTC299 in adult patients with ... the development of non-malignant brain tumors. PTC299 is a ... selectively block tumor-related vascular endothelial growth factor (VEGF). With ...
Cached Biology Technology:Zimmer Launches New Medical Education and BioSkills Training Program 2Zimmer Launches New Medical Education and BioSkills Training Program 3Zimmer Launches New Medical Education and BioSkills Training Program 4NASA Extends Bioastronautics Contract With Wyle for Total Value of $976 Million 2PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 2PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 3PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 4
(Date:11/4/2014)... 2014 – University of Utah engineers developed the first ... fuel produce electricity without needing to ignite the fuel. ... portable electronics, off-grid power and sensors. , A study ... American Chemical Society journal ACS Catalysis . , ... reaction between a fuel and an oxygen-rich source such ...
(Date:11/4/2014)... newly published research study examining only marketing directed ... fast food restaurants has found that the majority ... exposed to such marketing tactics. , Authored by ... colleagues, the study is the first to examine ... and exterior of fast food restaurants and its ...
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... burn cleaner, a research report published in the January ... the food industry could take a similar approach toward ... additives would be based on work of Israeli researchers ... wine, fruits, and vegetables) simultaneously with high-fat foods may ...
... a higher prevalence of body abnormalities, such as asymmetric lower ... defect responsible for the abnormality may play a role in ... January 2 issue of JAMA. Certain genetic syndromes ... cancer development in children. Several studies have shown that developmental ...
... that doctors treating life-threatening emergencies such as allergy attacks may ... labelling. Adrenaline is stored in salt water in glass ... The amount of adrenaline contained in the ampoule is ... drug per 1 mL of salt water) and a ratio ...
Cached Biology News:Study examines genetic defects linked to body abnormalities in patients with childhood cancer 2Doctors may be giving the wrong dosage of adrenaline in an emergency because of labelling 2
Human PDGF, CF...
... utility and flexibility press-to-seal silicone isolators can ... the researcher. They are available either pre-cut ... material that can be easily trimmed to ... and non-cytotoxic and can be used to ...
... The mycobacteria in Complete Freund's ... the injection site which enhances the immuneresponse. ... is used for the initial injections; Incomplete ... boosts. Antigens (preferably in saline) are typically ...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
Biology Products: